Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$10.73B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  NURO
NeuroMetrix
NURO
56 / 100
Penny Stock
$4.430.00%-$0.00

Performance History

Stocklytics logo
Key Stats
Open$4.69
Prev. Close$4.57
EPS-6.27
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap9078488.00
PE Ratio-
LOWHIGH
Day Range4.22
4.69
52 Week Range0.45
11.68
Ratios
P/B Ratio0.37
Revenue$5.90M
Operating M. %-140.93%
Earnings$0.00
Earnings Growth %-47.84%
EBITDA Margin %-120.24%
ROE %-30.06%
EPS-6.27

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

56vs 56. Market Avg.

All Score 56 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

NUROMARKET
Value4040
Quality3240
Ownership917
Growth7347
Dividends-38
check_circle

NeuroMetrix 's Price discount from all time high of 100% is great compared to market average of 42.77%. This indicates NURO could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$731.33
24H (%)arrow_drop_up0.69%
24H ($)$5.02
MARKET CAP$695.32B
PRICE$491.23
24H (%)arrow_drop_down1.97%
24H ($)-$9.89
MARKET CAP$462.00B
PRICE$149.12
24H (%)arrow_drop_up0.81%
24H ($)$1.20
MARKET CAP$359.34B
PRICE$126.94
24H (%)arrow_drop_up0.92%
24H ($)$1.16
MARKET CAP$318.60B

About NeuroMetrix (NURO)

NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.

Sector
Healthcare
Industry
Medical Devices
CEO
Dr. Shai N. Gozani M.D., Ph.D.
Headquarters
Woburn
Employees
27
Exchange
NASDAQ
add NeuroMetrix  to watchlist

Keep an eye on NeuroMetrix

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is NeuroMetrix 's (NURO) price per share?

The current price per share for NeuroMetrix (NURO) is $4.57. The stock has seen a price change of $0.24 recently, indicating a 5.54% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for NeuroMetrix (NURO)?

For NeuroMetrix (NURO), the 52-week high is $11.68, which is 155.58% from the current price. The 52-week low is $0.45, the current price is 915.56% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is NeuroMetrix (NURO) a growth stock?

NeuroMetrix (NURO) has shown an average price growth of 58.18% over the past three years. It has received a score of 92 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NeuroMetrix as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is NeuroMetrix (NURO) stock price performance year to date (YTD)?

As of the latest data, NeuroMetrix (NURO) has a year-to-date price change of 32.74%. Over the past month, the stock has experienced a price change of 12.01%. Over the last three months, the change has been 52.33%.

help
Is NeuroMetrix (NURO) a profitable company?

NeuroMetrix (NURO) has a net income of -$6.53M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 66.89% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -140.93% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $5.9M, although specific revenue growth data is currently not available. The gross profit is $3.95M. Operating income is noted at -$7.15M. Furthermore, the EBITDA is -$7.1M.

help
What is the market capitalization of NeuroMetrix (NURO)?

NeuroMetrix (NURO) has a market capitalization of $8.6M. The average daily trading volume is 44.55K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.